OBJECTIVE: To determine whether hospital length of stay(LOS) for acute bronchiolitis is influenced by the infecting pathogen. DESIGN: A prospective observational cohort study was performed during 3 consecutive years. SETTING: Sixteen US hospitals participated in the study. PARTICIPANTS: Children younger than 2 years hospitalized with bronchiolitis were included. MAIN EXPOSURE: The results of nasopharyngeal aspirate polymerase chain reaction pathogen testing served as the main exposure. MAIN OUTCOME MEASURE: Hospital LOS was determined. RESULTS: Of 2207 participants, 72.0% had respiratory syncytial virus (RSV) and 25.6% had human rhinovirus(HRV); the incidence of each of the other viruses and bacteria was 7.8% or less. Multiple pathogen infections were present in 29.8% of the children. There were 1866 children(84.5%) with RSV and/or HRV. Among these 1866 children, the median age was 4 months and 59.5% were male. The median LOS was 2 days (interquartile range,1-4 days). Compared with children who had only RSV,an LOS of 3 or more days was less likely among children with HRV alone (adjusted odds ratio [AOR], 0.36; 95%CI, 0.20-0.63; P.001) and those with HRV plus non-RSV pathogens (AOR, 0.39; 95% CI, 0.23-0.66; P.001)but more likely among children with RSV plus HRV(AOR,1.33; 95% CI, 1.02-1.73; P=.04), controlling for 15 demographic and clinical factors. CONCLUSIONS: In this multicenter study of children hospitalized with bronchiolitis, RSV was the most common virus detected, but HRV was detected in one-quarter of the children. Since 1 in 3 children had multiple virus infections and HRV was associated with LOS, these data challenge the effectiveness of current RSV-based cohorting practices, the sporadic testing for HRV in bronchiolitis research, and current thinking that the infectious etiology of severe bronchiolitis does not affect short-term outcomes.
OBJECTIVE: To determine whether hospital length of stay(LOS) for acute bronchiolitis is influenced by the infecting pathogen. DESIGN: A prospective observational cohort study was performed during 3 consecutive years. SETTING: Sixteen US hospitals participated in the study. PARTICIPANTS: Children younger than 2 years hospitalized with bronchiolitis were included. MAIN EXPOSURE: The results of nasopharyngeal aspirate polymerase chain reaction pathogen testing served as the main exposure. MAIN OUTCOME MEASURE: Hospital LOS was determined. RESULTS: Of 2207 participants, 72.0% had respiratory syncytial virus (RSV) and 25.6% had human rhinovirus(HRV); the incidence of each of the other viruses and bacteria was 7.8% or less. Multiple pathogen infections were present in 29.8% of the children. There were 1866 children(84.5%) with RSV and/or HRV. Among these 1866 children, the median age was 4 months and 59.5% were male. The median LOS was 2 days (interquartile range,1-4 days). Compared with children who had only RSV,an LOS of 3 or more days was less likely among children with HRV alone (adjusted odds ratio [AOR], 0.36; 95%CI, 0.20-0.63; P.001) and those with HRV plus non-RSV pathogens (AOR, 0.39; 95% CI, 0.23-0.66; P.001)but more likely among children with RSV plus HRV(AOR,1.33; 95% CI, 1.02-1.73; P=.04), controlling for 15 demographic and clinical factors. CONCLUSIONS: In this multicenter study of children hospitalized with bronchiolitis, RSV was the most common virus detected, but HRV was detected in one-quarter of the children. Since 1 in 3 children had multiple virus infections and HRV was associated with LOS, these data challenge the effectiveness of current RSV-based cohorting practices, the sporadic testing for HRV in bronchiolitis research, and current thinking that the infectious etiology of severe bronchiolitis does not affect short-term outcomes.
Authors: L Bont; C J Heijnen; A Kavelaars; W M van Aalderen; F Brus; J M Draaisma; M Pekelharing-Berghuis; R A van Diemen-Steenvoorde; J L Kimpen Journal: J Infect Dis Date: 2001-06-26 Impact factor: 5.226
Authors: Julie Greensill; Paul S McNamara; Winifred Dove; Brian Flanagan; Rosalind L Smyth; C Anthony Hart Journal: Emerg Infect Dis Date: 2003-03 Impact factor: 6.883
Authors: Anne Kotaniemi-Syrjänen; Raija Vainionpää; Tiina M Reijonen; Matti Waris; Kaj Korhonen; Matti Korppi Journal: J Allergy Clin Immunol Date: 2003-01 Impact factor: 10.793
Authors: Jonathan M Mansbach; Alexander J McAdam; Sunday Clark; Paul D Hain; Robert G Flood; Uchechi Acholonu; Carlos A Camargo Journal: Acad Emerg Med Date: 2008-02 Impact factor: 3.451
Authors: Kohei Hasegawa; Jonathan M Mansbach; Yury A Bochkov; James E Gern; Pedro A Piedra; Cindy S Bauer; Stephen J Teach; Susan Wu; Ashley F Sullivan; Carlos A Camargo Journal: JAMA Pediatr Date: 2019-06-01 Impact factor: 16.193
Authors: J Michael Miller; Matthew J Binnicker; Sheldon Campbell; Karen C Carroll; Kimberle C Chapin; Peter H Gilligan; Mark D Gonzalez; Robert C Jerris; Sue C Kehl; Robin Patel; Bobbi S Pritt; Sandra S Richter; Barbara Robinson-Dunn; Joseph D Schwartzman; James W Snyder; Sam Telford; Elitza S Theel; Richard B Thomson; Melvin P Weinstein; Joseph D Yao Journal: Clin Infect Dis Date: 2018-08-31 Impact factor: 9.079
Authors: Carlos E Rodríguez-Martínez; Jose A Castro-Rodriguez; Gustavo Nino; Fabio Midulla Journal: Paediatr Respir Rev Date: 2019-04-12 Impact factor: 2.726
Authors: Erin G Nicholson; Chelsea Schlegel; Roberto P Garofalo; Reena Mehta; Margaret Scheffler; Minghua Mei; Pedro A Piedra Journal: J Infect Dis Date: 2016-05-18 Impact factor: 5.226
Authors: Santtu Heinonen; Tuomas Jartti; Carla Garcia; Silvia Oliva; Cynthia Smitherman; Esperanza Anguiano; Wouter A A de Steenhuijsen Piters; Tytti Vuorinen; Olli Ruuskanen; Blerta Dimo; Nicolas M Suarez; Virginia Pascual; Octavio Ramilo; Asuncion Mejias Journal: Am J Respir Crit Care Med Date: 2016-04-01 Impact factor: 21.405